Human VKORc1 catalyzes the regeneration of active vitamin K to support blood coagulation and is the target of oral vitamin K antagonists such as warfarin, which is widely used to treat and prevent thromboembolic diseases (20). Here, VKORC1 is linked to Thromboembolism.